300502.SZ · A-shares

300502.SZ Eoptolink: high-beta optical modules

Eoptolink Same AI optics theme as Innolight, often higher beta—watch hyperscaler share, 800G/1.6T cadence, and GM swings.

Published Updated Open interactive reader

Download MarkdownExport PDF

Cite a section with a deep link, e.g. /en/r/eoptolink-300502-research#thesis

Snapshot

Price
CNY 350
Mkt cap
CNY 600.0B
Revenue
CNY 12.0B
High-speed mix momentum
1.6
As of 2026-09-25

As-of 2026-09-25 (weekly refresh; equities aligned to §A. Missing series are N/A/null. Not investment advice.)

Thesis

Eoptolink Same AI optics theme as Innolight, often higher beta—watch hyperscaler share, 800G/1.6T cadence, and GM swings.

Business

Model: optical module R&D/manufacturing. Flagships: high-speed datacom optics. Edge: speed-to-market and cost. Strategy: follow cluster speed upgrades.

Value chain

Optical midstream; similar supply/customer risks to Innolight—concentration, price war, optical chips.

Valuation

Valuation snapshot (multi-lens)

Valuation snapshot (multi-lens)
MetricValueNote
TTM PEN/A未接入具名行情源;TTM 盈利≤0 或未核验时不填造倍数
PBN/A待最新净资产与市值核验
股息率N/A待分红公告 / IR
现价语境约 350300502.SZ · 以包内 kpi_snapshot 时点为准
As of 2026-09-25

Valuation & return · ~3y

Interactive chart available in the reader.

PE/PB/yield/return points are null until a named market source is wired; no linear fill. · As of 2026-09-25

High-beta growth; more volatile than category leaders.

Financial trend (~24 months)

Illustrative 8Q with YoY/QoQ (reconstructed from public disclosures; not audit-line):

Revenue · last 8Q

Interactive chart available in the reader.

Reconstructed from public filings/guidance (illustrative) · As of 2026-09-25

Gross margin · last 8Q

Interactive chart available in the reader.

Reconstructed from public filings/guidance (illustrative) · As of 2026-09-25

Net income · last 8Q

Interactive chart available in the reader.

Reconstructed from public filings (illustrative; attributable NI) · As of 2026-09-25

Financial health (§A.7)

Financial health (OCF / debt / liquidity / audit)

Financial health (OCF / debt / liquidity / audit)
ItemValueNote
财务健康总评见最新披露以 OCF 与负债率为准
经营现金流见中报 / 季报与净利润匹配度
资产负债率见最新资产负债表有息负债 vs 现金
流动性见流动比率货币资金与短债
审计意见无保留(常规预期)半年报未经审计
As of 2026-09-25

Operations

Same volume/price/cost frame as optical peers.

Key financials

Key financials
ItemValueYoYNote
赛道数通光模块AI 驱动与旭创同逻辑
增长高速产品放量高增代际
估值进入 A 股前列科技市值波动大2026 叙事
竞争与旭创等抢份额激烈价格/产能
As of 2026-09-25

Competition

Peer strengths/weaknesses:

Market share trend · last 8Q

Interactive chart available in the reader.

Industry reports + public disclosures (illustrative estimate) · As of 2026-09-25

Peer market share comparison (latest est.)

Interactive chart available in the reader.

Industry reports + public disclosures (illustrative estimate) · As of 2026-09-25

Peer map

Peer map
CompanyShare/roleMarginStrengthWeakness
新易盛高速模块高弹性客户集中
中际旭创龙头高份额估值也贵
天孚器件高配套产品不同
海外光通信多元中品牌中国厂商替代
As of 2026-09-25

Management

Management (24m)

Management (24m)
RoleNameSince24m change
董事长/总经理核心团队光通信背景连续
CFO财务负责人在任稳定
销售/大客户关键岗位北美云订单关键
As of 2026-09-25

Stability: Management focused on optics; strategy tied to industry beta.

Outlook

Same watches as Innolight: speed ramps, GM, cloud CapEx.

Scenarios

Scenario Condition Implication
Bull Demand/execution beats Upside
Base Trend continues Hold/watch
Bear Cycle/competition worsens Drawdown/reassess

Risks

References

Issuer / key sources:

  1. Latest company filings / IR (see issuer website)
  2. Exchange filings / SEC EDGAR — https://www.sec.gov/edgar
  3. Related on-site notes via wiki-links in the body

Not investment advice; defer to latest company filings.

Tracking

Check next earnings for:

  1. Next-quarter revenue & margin vs guide
  2. OCF vs CapEx / payout
  3. Competitive share shifts
  4. Valuation vs historical mid-cycle
  5. Key policy / supply-chain variables

Confirm: guide hit, share stable, OCF matches earnings.
Disconfirm: guide cut, share loss, leverage stress.

Disclaimer: For research information only. Not investment advice or a recommendation to buy or sell.

Comments

Sign in to comment

Loading…